Bosnalijek (SASE: BSNLR), Bosnia and Herzegovina’s largest drugmaker, is considering building a plant for the production of its drugs in the Russian city of Kaluga, according to the company, reports The Pharma Letter’s local correspondent.
It is reported that the plant will specialize on the production solid dosage forms, although its planned range is not disclosed.
Financial details of the project are not disclosed, however, according to some sources close to the company, the value of investments may be in the range of $30-$50 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze